What Has Been The Evolution of the Alzheimers Disease Treatment Market in Recent Years?
The alzheimers disease treatment market has seen considerable growth due to a variety of factors.
• The market size for Alzheimer’s disease treatment has significantly expanded in the past few years. It is projected to surge from $5.93 billion in 2024 to $6.41 billion in 2025, with a compound annual growth rate (CAGR) of 8.2%.
Factors such as advancements in scientific research and comprehension, the approval and introduction of new drugs, governmental support and funding, and increased public consciousness and education have contributed to the growth during the historical period.
What Is the Forecasted Market Size and Growth Rate for The Alzheimers Disease Treatment Market Size In The Coming Years?
The alzheimers disease treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for alzheimer’s disease treatment is predicted to experience significant expansion in the upcoming years, with projections to reach $8.35 billion in 2029, reflecting a compound annual growth rate (CAGR) of 6.8%.
The expected growth during the forecast period is due to factors such as the development of precision medicine methodologies, increase in healthcare spending, the worldwide disease burden, advancements in genetic and biomarker research, and growth in emerging markets. The forecast period will also witness considerable trends such as breakthroughs in biotechnology, progress in technological innovations, advancements in digital health technologies, the use of precision medicine, modulation of neuroinflammation, and the prevalence of collaborations and partnerships.
What Factors Are Driving Growth In The Alzheimers Disease Treatment Market?
The escalating incidences of Alzheimer's are significantly influencing the expansion of the Alzheimer’s disease treatment market. Alzheimer's represents the most prevalent kind of dementia. The USA Alzheimer's Association anticipates all US states to experience an increase of at least 14% in Alzheimer’s patients by 2025, attributed to the ageing population. Globally, the predicted new cases of Alzheimer’s are projected to surge by 35% to 615,000 by 2030, and a substantial 110% increase to 959,000 by 2050. Hence, the rising occurrence of Alzheimer’s disease is poised to fuel the demand for growth in the global Alzheimer’s disease treatment market.
What Are The Main Segments Of The Global Alzheimers Disease Treatment Market?
The alzheimer’s disease treatment market covered in this report is segmented –
1) By Drug Class: Cholinergic, Memantine, Combined Drug, AChE inhibitors, Immunoglobulins
2) By Drug Type: Cholinesterase Inhibitors, NMDA Receptor Antagonists
3) By Therapeutics: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Other Therapeutics
Subsegments:
1) By Cholinergic: Donepezil, Galantamine, Rivastigmine
2) By Memantine: Memantine Hydrochloride, Extended-Release Memantine
3) By Combined Drug: Donepezil and Memantine Combination
4) By AChE Inhibitors: Tacrine, Physical Inhibitors
5) By Immunoglobulins: IVIG (Intravenous Immunoglobulin), Monoclonal Antibodies
Pre-Book The Alzheimers Disease Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Alzheimers Disease Treatment Market?
Top businesses in the Alzheimer's disease treatment market are prioritizing regulatory certifications to fortify their competitive stance and expand their product line. Regulatory certifications denote the official permission given by governmental bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) to market and sell a product to consumers. To illustrate, Eli Lilly and Company, an American pharmaceutical firm, attained FDA sanction for its Alzheimer's remedy, Kisunla (donanemab-azbt), in July 2024. Recommended for adults showing early signs of Alzheimer's, including mild cognitive deficits and mild dementia, Kisunla is dispensed through monthly IV infusion and has proven effective in retarding Alzheimer's progression during clinical tests. Its approval signals its potential influence, as it has been granted Fast Track, Priority Review, and Breakthrough Therapy designations.
Who Are the Key Players In The Alzheimers Disease Treatment Market?
Major companies operating in the alzheimer’s disease treatment market include:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Merck Sharp & Dohme Corp.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Biogen Inc.
• UCB S.A.
• Eisai Co. Ltd.
• Forest Laboratories LLC
• Ono Pharmaceutical Co. Ltd.
• H. Lundbeck A/S
• Allergan plc
• Luye Pharma Group
• Avanir Pharmaceuticals Inc.
• Denali Therapeutics Inc.
• Athira Pharma Inc.
• ProMIS Neurosciences Inc.
• AC Immune SA
• vTv Therapeutics Inc.
• AB Science SA
• TauRx Pharmaceuticals Ltd.
• Alzheon Inc.
What Is The Most Dominant Region In The Alzheimers Disease Treatment Market?
North America is the largest region in the Alzheimer’s disease treatment market in 2024. Middle East is expected to be the fastest growing region in the Alzheimer’s disease treatment market share during the forecast period. The regions covered in the Alzheimer’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
